FDA regulators issue another warning letter for Hospira following an inspection of a North Carolina manufacturing facility that has been under the microscope since 2010. Infusion technologies maker Hospira (NYSE:HSP) remains in the FDA’s cross-hairs after agency inspectors asked for more information about a North Carolina manufacturing facility that has been in hot water for years. In the new warning, FDA officials cited at least 1 device malfunction in the field associated with injection systems that failed leak testing but were nonetheless allowed on shelves.
Help employers find you! Check out all the jobs and post your resume.
